Hypercoagulable State

  • Andrew I. Schafer


  • The term hypercoagulable states is used interchangeably with thrombophilia or prethrombotic state to refer to hereditary or acquired conditions that predispose individuals to thrombosis.

  • The coagulation system, also known as the coagulation cascade, is a highly coordinated and tightly linked series of enzymatic reactions, involving the sequential conversion of plasma clotting factors that circulate in their inactive zymogen forms to enzymatically active serine proteases, culminating in the formation of fibrin.

  • The coagulation system is normally kept in check by several physiological anticoagulant (antithrombotic) mechanisms. These include antithrombin III, the protein C/protein S/thrombomodulin system, tissue factor pathway inhibitor, the protein Z/protein Z-dependent protease inhibitor system, and the fibrinolytic system.

  • Primary hypercoagulable states are mostly inherited thrombophilias caused by (1) quantitative deficiencies or qualitative defects of the physiologic anticoagulants, or (2) increased levels or function of the coagulation factors.

  • Secondary hypercoagulable states encompass a variety of diseases and conditions, most of which are acquired, which predispose individuals to thrombosis by complex and multifactorial mechanisms.

  • In gene-gene interactions, the inheritance of more than one thrombophilic defect leads to an increased lifelong risk of thrombosis.

  • In gene-environment interactions, many thrombotic complications in individuals with inherited (primary) hypercoagulable states are precipitated by acquired, acute thrombogenic insults, pointing to complex interactions between genetic and environmental factors in the pathogenesis of clinical thrombotic events.

  • The hypercoagulable workup is a laboratory evaluation of individuals with suspected hypercoagulable states. It is guided by the history, physical examination, and implications for management decisions.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001;47:1597–1606.PubMedGoogle Scholar
  2. 2.
    Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Br J Haemotol 2001;114:512–528.Google Scholar
  3. 3.
    Virchow R. Gesammalte Abhandlungen zur Wissenschaftlichen Medtzin. Frankfurt, Germany: Medinger Sohn, 1856:219–732.Google Scholar
  4. 4.
    Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003;23:17–25.PubMedGoogle Scholar
  5. 5.
    Jenny NS, Mann KG. Coagulation cascade: an overview. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003:1–21.Google Scholar
  6. 6.
    Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, Pike RN. Antithrombin: in control of coagulation. Int J Biochem Cell Biol 2004;36:386–389.PubMedGoogle Scholar
  7. 7.
    Simmonds RE, Rance J, Lane DA. Regulation of coagulation. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003:35–61.Google Scholar
  8. 8.
    Aird WC. Natural anticoagulant inhibitors: activated protein C. Best Pract Res Clin Haematol 2004;17:161–182.PubMedGoogle Scholar
  9. 9.
    Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004;79:109–116.PubMedGoogle Scholar
  10. 10.
    Esmon CT. The protein C pathway. Chest 2003;124(3 suppl):26S–32S.PubMedGoogle Scholar
  11. 11.
    Weiler H. Mouse models of thrombosis: thrombomodulin. Thromb Haemost 2004;92:467–477.PubMedGoogle Scholar
  12. 12.
    Rigby AC, Grant MA. Protein S: a conduit between anticoagulation and inflammation. Crit Care Med 2004;32(5 suppl):S336–S341.PubMedGoogle Scholar
  13. 13.
    Broze GJ Jr. The tissue factor pathway of coagulation. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage, 3rd ed. Philadelphia: Lippincott, Williams & Wilkins, 2003:62–80.Google Scholar
  14. 14.
    Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003;89:610–621.PubMedGoogle Scholar
  15. 15.
    Ploplis VA, Castellino FJ. Gene targeting of components of the fibrinolytic system. Thromb Haemost 2002;87:22–31.PubMedGoogle Scholar
  16. 16.
    Nesheim M. Thrombin and fibrinolysis. Chest 2003;124(3 suppl):33S–39S.PubMedGoogle Scholar
  17. 17.
    Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2003;33:375–381.PubMedGoogle Scholar
  18. 18.
    Schafer AI, Levine MN, Konkle BA, Kearon C. Thrombotic disorders: diagnosis and treatment. Hematology (Am Soc Hematol Educ Program) 2003:520–539.Google Scholar
  19. 19.
    Arkel YS, Paidas MJ, Ku DH. The use of coagulation activation markers (soluble fibrin monomer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coag Fibrinolys 2002;13:199–205.Google Scholar
  20. 20.
    Gouin-Thibault I, Arkam R, Nassiri S, et al. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. Thromb Res 2002;107:7–11.PubMedGoogle Scholar
  21. 21.
    Ariens RA, de Lange M, Snieder H, et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lance 2002;359:667–671.Google Scholar
  22. 22.
    Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonistmediated vascular desensitization. N Engl J Med 2001;345:1030–1035.PubMedGoogle Scholar
  23. 23.
    Brinsuk M, Tank J, Luft FC, et al. Heritability of venous function in humans. Arterioscler Thromb Vasc Biol 2004;24:207–211.PubMedGoogle Scholar
  24. 24.
    Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003;138:128–134.PubMedGoogle Scholar
  25. 25.
    Mannucci PM. The molecular basis of inherited thrombophilia. Vox Sang 2000;78(suppl 2):39–45.Google Scholar
  26. 26.
    Bucciarelli P, Rosendaal FR, Tripodi A, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999;19:1026–1033.PubMedGoogle Scholar
  27. 27.
    Wu LA, Malouf JF, Dearani JA, et al. Patent foramen ovale in cryptogenic stroke: current understanding and management options. Arch Intern Med 2004;164:950–956.PubMedGoogle Scholar
  28. 28.
    Horton SC, Bunch TJ. Patent foramen ovale and stroke. Mayo Clin Proc 2004;79:79–88.PubMedGoogle Scholar
  29. 29.
    Rodriguez CJ, Homma S. Management of patients with stroke and a patent foramen ovale. Curr Cardiol Rep 2004;6:143–146.PubMedGoogle Scholar
  30. 30.
    Mas J-L, Arquizan C, Lany C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. N Engl J Med 2001;345:1740–1746.PubMedGoogle Scholar
  31. 31.
    Overall JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000;55:1172–1179.Google Scholar
  32. 32.
    Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003;348:1435–1441.PubMedGoogle Scholar
  33. 33.
    Voetsch B, Loscalzo J. Genetics of thrombophila: impact on atherogenesis. Curr Opin Lipidol 2004;15:129–143.PubMedGoogle Scholar
  34. 34.
    Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001;161:1405–1410.PubMedGoogle Scholar
  35. 35.
    Schafer AI. Thrombotic disorders: hypercoagulable states. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: WB Saunders, 2004:1082–1087.Google Scholar
  36. 36.
    Bauer KA. Inherited and acquired hypercoagulable states. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003:648–684.Google Scholar
  37. 37.
    Bauters A, Zawadski C, Bura A, et al. Homozygous variant of antithrombin with lack of affinity for heparin: management of severe thrombotic complications associated with intrauterine fetal demise. Blood Coagul Fibrinolysis 1996;7:705–710.PubMedGoogle Scholar
  38. 38.
    Martinelli I, Mannucci PM, DeStefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998;92:2353–2358.PubMedGoogle Scholar
  39. 39.
    Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990;16:299–309.PubMedGoogle Scholar
  40. 40.
    Mitchell CA, Rowell JA, Hau L, et al. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987;317:1638–1642.PubMedGoogle Scholar
  41. 41.
    Liaw PC, Mather T, Oganesyan N, et al. Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor. Implications for a novel mode of ligand recognition by a major histocompatibility complex class 1-type receptor. J Biol Chem 2001;276:8364–8370.PubMedGoogle Scholar
  42. 42.
    Faioni EM, Franchi F, Castaman G, et al. Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia. Br J Haematol 2002;118:595–599.PubMedGoogle Scholar
  43. 43.
    Borgel D, Gandrille S. Aiach M. Protein S deficiency. Thromb Haemost 1997;78:351–356.PubMedGoogle Scholar
  44. 44.
    Beauchamp N, Dykes AC, Parikh N, et al. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol 2004;125:647–654.PubMedGoogle Scholar
  45. 45.
    Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004–1008.PubMedGoogle Scholar
  46. 46.
    Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67.PubMedGoogle Scholar
  47. 47.
    Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396–1400.PubMedGoogle Scholar
  48. 48.
    Nicolaes GA, Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002;22:530–538.PubMedGoogle Scholar
  49. 49.
    Mumford AD, McVey JH, Morse CV, et al. Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol 2003;123:496–501.PubMedGoogle Scholar
  50. 50.
    Dargaud Y, Trzeciak MC, Meunier S, et al. Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy. Br J Haematol 2003;123:342–345.PubMedGoogle Scholar
  51. 51.
    Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999;19:511–518.PubMedGoogle Scholar
  52. 52.
    Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305–1307.PubMedGoogle Scholar
  53. 53.
    Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002;126:1304–1318.PubMedGoogle Scholar
  54. 54.
    Dowling NF, Austin H, Dilley A, et al. The epidemiology of venous thromboembolism in Caucasians and African-Americans: The GATE study. J Thromb Haemost 2003;1:80–87.PubMedGoogle Scholar
  55. 55.
    Castoldi E, Kalafatis M, Lunghi B, et al. Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thromb Haemost 1998;80:403–406.PubMedGoogle Scholar
  56. 56.
    Martinelli I, Cattaneo M, Panzeri D, Mannucci PM. Low prevalence of factor V: Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997;77:440–443.PubMedGoogle Scholar
  57. 57.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood 1996;88:3698–3703.PubMedGoogle Scholar
  58. 58.
    McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med 2002;126:1319–1325.PubMedGoogle Scholar
  59. 59.
    Dilley A, Austin H, Hooper WC, et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 1998;132:452–455.PubMedGoogle Scholar
  60. 60.
    Nachman RL. Hypercoagulable states: challenges and opportunities. Trans Am Clin Climatol Assoc 2001;112:161–179.PubMedGoogle Scholar
  61. 61.
    Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2002;113:636–642.PubMedGoogle Scholar
  62. 62.
    Meijers JCM, Tekelenburg WLH, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696–701.PubMedGoogle Scholar
  63. 63.
    Van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678–3682.PubMedGoogle Scholar
  64. 64.
    Kraaijenhagen RA, in’t Anker PS, Koopman MMW, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5–9.PubMedGoogle Scholar
  65. 65.
    Souto JC, Almasy L, Soria JM, et al. Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project. Thromb Haemost 2003;89:468–474.PubMedGoogle Scholar
  66. 66.
    Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms—the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994;71:719–722.PubMedGoogle Scholar
  67. 67.
    Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004;351:1081–1088.PubMedGoogle Scholar
  68. 68.
    Cristina L, Benilde C, Michela C, et al. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004;124:504–510.PubMedGoogle Scholar
  69. 69.
    Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457–462.PubMedGoogle Scholar
  70. 70.
    Brandt JT. Plasminogen and tissue-type plasminogen activator deficiency as risk factor for thromboembolic disease. Arch Pathol Lab Med 2002;126:1376–1381.PubMedGoogle Scholar
  71. 71.
    Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 2002;126:1401–1404.PubMedGoogle Scholar
  72. 72.
    van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000;95:2855–2859.PubMedGoogle Scholar
  73. 73.
    Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Thromb Haemost 1995;73:151–161.PubMedGoogle Scholar
  74. 74.
    Hamano A, Mimuro J, Aoshima M, et al. Thrombophilic dys-fibrinogen Tokyo V with the amino acid substitution of Ala327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism. Blood 2004;103:3045–3050.PubMedGoogle Scholar
  75. 75.
    Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005;105:1102–1105.PubMedGoogle Scholar
  76. 76.
    Dahm A, van Hylckama Vlieg A, Bendz B, et al. Low levels of tissue factor pathway inhibitor (TFPI) increases the risk of venous thrombosis. Blood 2003;101:4387–4392.PubMedGoogle Scholar
  77. 77.
    Van de Water N, Tan T, Ashton F, et al. Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol 2004;127:190–194.PubMedGoogle Scholar
  78. 78.
    Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many tests, too much conflicting data. Hematology (Am Soc Hematol Educ Program) 2002;353–368.Google Scholar
  79. 79.
    Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585–593.PubMedGoogle Scholar
  80. 80.
    Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Thromb Haemost 2000;83:657–660.PubMedGoogle Scholar
  81. 81.
    Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309–1311.PubMedGoogle Scholar
  82. 82.
    Ozturk MA, Haznedaroglu IC, Turgut M, Goker H. Current debates in antiphospholipid syndrome: the acquired antibody-mediated thrombophilia. Clin Appl Thromb Hemost 2004;10:89–126.PubMedGoogle Scholar
  83. 83.
    Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 2003;48:3320–3327.PubMedGoogle Scholar
  84. 84.
    Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systemic review of the literature. Blood 2003;101:1827–1832.PubMedGoogle Scholar
  85. 85.
    Bas de Laat H, Derksen RHWM, Urbanus RT, et al. α2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004;104:3598–3602.PubMedGoogle Scholar
  86. 86.
    Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990:147–159.Google Scholar
  87. 87.
    Kakkar AK. Thrombosis and cancer. Hematol J 2004;5(suppl 3):S20–S23.PubMedGoogle Scholar
  88. 88.
    Lee AY, Levine MN, Baker RI, Bowden C. A randomized trial of long term dalteparin low molecular weight heparin versus oral anticoagulant therapy in cancer patients with venous thromboembolism. N Engl J Med 2003;349:146–153.PubMedGoogle Scholar
  89. 89.
    Greer LA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258–1265.PubMedGoogle Scholar
  90. 90.
    Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002;100:3470–3478.PubMedGoogle Scholar
  91. 91.
    Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 2004;164:1965–1976.PubMedGoogle Scholar
  92. 92.
    van den Bosch MAAJ, Kemmeren JM, Tanis BC, et al. The RATIO Study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost 2003;1:439–444.Google Scholar
  93. 93.
    Tanis BC, van den Bosch MAAJ, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787–1793.PubMedGoogle Scholar
  94. 94.
    Baumann P, Diedrich K. Thromboembolic complications associated with reproductive endocrinologic procedures. Hematol/Oncol Clin North Am 2000;14:431–443.Google Scholar
  95. 95.
    Post MS, Rosing J, van der Mooren MJ, et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol 2002;119:1017–1023.PubMedGoogle Scholar
  96. 96.
    Rogers FB. Venous thromboembolism in trauma patients: a review. Surgery 2001;130:1–12.PubMedGoogle Scholar
  97. 97.
    Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after trauma. N Engl J Med 1994;331:1601–1606.PubMedGoogle Scholar
  98. 98.
    Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701–707.PubMedGoogle Scholar
  99. 99.
    Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation 2005;110(suppl IV):IV-4–IV-12.Google Scholar
  100. 100.
    Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):338S–400S.PubMedGoogle Scholar
  101. 101.
    Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452–463.PubMedGoogle Scholar
  102. 102.
    Bosson JL, Labarere J, Sevestre MA, et al. Deep vein thrombosis in elderly patients hospitalized in subacute care facilities: a multicenter cross-sectional study of risk factors, prophylaxis, and prevalence. Arch Intern Med 2003;163:2613–2618.PubMedGoogle Scholar
  103. 103.
    Kelly J, Rudd A, Lewis R, et al. Venous thromboembolism after acute stroke. Stroke 2001;32:262–267.PubMedGoogle Scholar
  104. 104.
    Leizorovicz A, Mismetti P. Preventing venous thromboembolism in medical patients. Circulation 2004;110(suppl IV):IV-13–IV-19.Google Scholar
  105. 105.
    Dalen JE. Economy class syndrome. Too much flying or too much sitting? (editorial). Arch Intern Med 2003;163:2674–2676.PubMedGoogle Scholar
  106. 106.
    Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001;345:779–783.PubMedGoogle Scholar
  107. 107.
    Perez-Rodriguez E, Jimenez D, Diaz G, et al. Incidence of air travel-related pulmonary embolism at the Madrid-Barajas airport. Arch Intern Med 2003;163:2766–2770.PubMedGoogle Scholar
  108. 108.
    Schwartz T, Siegert G, Oettler W, et al. Venous thrombosis after long-haul flights. Arch Intern Med 2003:2759–2764.Google Scholar
  109. 109.
    Martinelli I, Tiaioli E, Battaglioli T, et al. Risk of venous thromboembolism after air travel. Arch Intern Med 2003;163:2771–2774.PubMedGoogle Scholar
  110. 110.
    Homans J. Thrombosis of the deep leg veins due to prolonged sitting. N Engl J Med 1954;250:148–149.PubMedGoogle Scholar
  111. 111.
    Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003;101:2483–2488.PubMedGoogle Scholar
  112. 112.
    Key NS, McGlennen RC. Hyperhomocyst(e)inemia and thrombophilia. Arch Pathol Lab Med 2002;126:1367–1375.PubMedGoogle Scholar
  113. 113.
    Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101–2106.PubMedGoogle Scholar
  114. 114.
    Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003;102:1363–1366.PubMedGoogle Scholar
  115. 115.
    Keijzer MBAJ, den Heijer M, Blom HJ, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolate reductase (MTHFR) and inherited thrombophilic factor in recurrent venous thrombosis. Thromb Haemost 2002;88:723–728.PubMedGoogle Scholar
  116. 116.
    Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophys Haemost Thromb 2002;32:51–58.Google Scholar
  117. 117.
    Quera R, Shanahan F. Thromboembolism—an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004;99:1971–1973.PubMedGoogle Scholar
  118. 118.
    Navarro S, Ricart JM, Medina P. Activated protein C levels in Behçet’s disease and risk of venous thrombosis. Br J Haematol 2004;126:550–556.PubMedGoogle Scholar
  119. 119.
    Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211–1219.PubMedGoogle Scholar
  120. 120.
    Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003;78:174–194.PubMedGoogle Scholar
  121. 121.
    Barbui T. Indications for lowering platelet numbers in essential thrombocythemia. Semin Hematol 2003;40(1 Suppl 1):22–25.PubMedGoogle Scholar
  122. 122.
    Landolfi R, Marchioli K, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–124.PubMedGoogle Scholar
  123. 123.
    Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003;115:721–728.PubMedGoogle Scholar
  124. 124.
    Setty BNY, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001;98:3228–3233.PubMedGoogle Scholar
  125. 125.
    Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99:36–43.PubMedGoogle Scholar
  126. 126.
    Atichartakam V, Chuncharunee S, Chandanamattha P, et al. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/β-thalassemic patient. Blood 2004;103:2844–2846.Google Scholar
  127. 127.
    Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999;93:3451–3456.PubMedGoogle Scholar
  128. 128.
    Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167–1173.PubMedGoogle Scholar
  129. 129.
    Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994;344:1739–1742.PubMedGoogle Scholar
  130. 130.
    Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995;85:3518–3523.PubMedGoogle Scholar
  131. 131.
    Van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996;75:417–421.PubMedGoogle Scholar
  132. 132.
    De Stafano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801–806.Google Scholar
  133. 133.
    Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997;170:1426–1429.Google Scholar
  134. 134.
    Eitzman DT, Westrick RJ, Bi X, et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002;105:2139–2142.PubMedGoogle Scholar
  135. 135.
    Soria JM, Almasy L, Souto JC, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003;101:163–167.PubMedGoogle Scholar
  136. 136.
    Westrick RJ, Manning SL, Dobies SL, et al. A sensitized genome-wide ENU mutagenesis screen in the mouse to identify genetic modifiers of thrombosis. Blood 2004;104:4a.Google Scholar
  137. 137.
    Schafer AI. Venous thrombosis as a chronic disease. N Engl J Med 1999;340:955–956.PubMedGoogle Scholar
  138. 138.
    Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1–7.PubMedGoogle Scholar
  139. 139.
    Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793–1797.PubMedGoogle Scholar
  140. 140.
    Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374–380.PubMedGoogle Scholar
  141. 141.
    Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715–722.PubMedGoogle Scholar
  142. 142.
    Samama M-M, Rached RA, Horellou M-H, et al. Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210A mutation and in heterozygous FII single gene mutation alone. Br J Haematol 2003;123:327–334.PubMedGoogle Scholar
  143. 143.
    Brouwer J-LP, Bijl M, Veeger NJGM, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004;104:143–148.PubMedGoogle Scholar
  144. 144.
    Schafer AI. Approach to the patient with bleeding and thrombosis. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: WB Saunders, 2004:975–979.Google Scholar
  145. 145.
    Bauer KA. Approach to thrombosis. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003:330–342.Google Scholar
  146. 146.
    Vossen CY, Preston FE, Conrad J, et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost 2004;2:592–596.PubMedGoogle Scholar
  147. 147.
    Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901–908.PubMedGoogle Scholar
  148. 148.
    Prandoni P, Lensing AWA, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128–1133.PubMedGoogle Scholar
  149. 149.
    Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet 1998;351:1077–1080.PubMedGoogle Scholar
  150. 150.
    Sorensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169–1173.PubMedGoogle Scholar
  151. 151.
    Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953–1958.PubMedGoogle Scholar
  152. 152.
    Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 2004;91:92–95.PubMedGoogle Scholar
  153. 153.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–1850.PubMedGoogle Scholar
  154. 154.
    Lee AY, Levine MN, Baker RI, Bowden C. A randomized trial of long term delteparin low molecular weight heparin versus oral anticoagulant therapy in cancer patients with venous thromboembolism. N Engl J Med 2003;349:146–153.PubMedGoogle Scholar
  155. 155.
    Tripodi A, Chantarangkul V, Martinelli I, et al. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004;104:3631–3634.PubMedGoogle Scholar
  156. 156.
    Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001;135:367–373.PubMedGoogle Scholar
  157. 157.
    Schulman S, Swenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332–338.PubMedGoogle Scholar
  158. 158.
    Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. Br Med J 1998;316:95–99.Google Scholar
  159. 159.
    Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: cost-effectiveness analysis. Thromb Haemost 2000;84:752–757.PubMedGoogle Scholar
  160. 160.
    Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies with deep vein thrombosis. Am J Med 2004;116:816–828.PubMedGoogle Scholar
  161. 161.
    Vink R, Kraaijenhagen RA, Levi M, Buller HR. Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost 2003;1:2523–2530.PubMedGoogle Scholar
  162. 162.
    Weitz JI, Middeldorp S, Geerts W, Heit JA. Thrombophilia and new anticoagulant drugs. Hematology (Am Soc Hematol Educ Program) 2004:424–438.Google Scholar
  163. 163.
    Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000;343:1439–1444.PubMedGoogle Scholar
  164. 164.
    Goldhaber SZ. Prevention of recurrent idiopathic venous thromboembolism. Circulation 2004;110(24 suppl 1):IV-20–IV-24.Google Scholar
  165. 165.
    Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004;11:192–197.PubMedGoogle Scholar
  166. 166.
    Prandoni P, Lensing AW, Prims MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955–960.PubMedGoogle Scholar
  167. 167.
    Palareti G, Legnani C, Cosmi B, et al. Predictive value of Ddimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313–318.PubMedGoogle Scholar
  168. 168.
    Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):401S–428S.PubMedGoogle Scholar
  169. 169.
    DeStefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996;87:3531–3544.Google Scholar

Copyright information

© Springer-Verlag London Limited 2007

Authors and Affiliations

  • Andrew I. Schafer
    • 1
  1. 1.Department of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations